Project Grant R44CA306565
Award Date 9/19/25
Completion Date 8/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94121, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant, CFDA 93.395 "Cancer Treatment Research", to the University of North Carolina at Chapel Hill (UNC-CH) in the amount of $627,456 on December 1, 2024. The purpose of this 5-year grant is to conduct a Phase I clinical trial evaluating the safety and efficacy of a CSPG4-targeted CAR-T cell therapy for the treatment of head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum-based chemotherapy and PD-1...
- The National Cancer Institute (NCI) awarded a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on August 25, 2025, supports the development and evaluation of DLL3-targeted, IL18-secreting chimeric antigen receptor (CAR) T cells for the treatment of small cell lung cancer (SCLC). The research aims to determine the safety and preliminary efficacy of this novel immunotherapy...
- The National Cancer Institute (NCI) awarded a $482,236 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports a biomarker-intensive, investigator-initiated Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) and the anti-EGFR antibody cetuximab for treating chemorefractory HER2-low metastatic colorectal cancer. The...
- The National Cancer Institute (NCI) awarded a $156,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Emory University to conduct research on the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The 2-year project aims to use an integrated multi-omics approach, including plasma metabolomics and white blood cell DNA methylation analysis, to comprehensively explore the systemic mechanisms underlying cachexia, a common and lethal...
- The U.S. National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, awarded on April 1, 2025 with a completion date of March 31, 2027, aims to synthesize and screen novel flupirtine analogue compounds that can effectively treat chemotherapy-induced neuropathic pain (CINP) without the...
- The Project Grant award "DISSECTING CCL5 CONTRIBUTION TO ANTIGEN SPECIFIC T CELL RESPONSES IN HEAD AND NECK CANCERS" is funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The $3,742,682 award supports research aimed at understanding the role of the CCL5 chemokine in shaping the tumor-specific T cell immune response in head and neck cancers. The research will leverage...
- The National Cancer Institute (NCI), under the federal Cancer Treatment Research Program (CFDA 93.395), has awarded a $276,544 project grant to Ioncologi Inc. to develop IOI7, a therapy utilizing autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cells (HSC), for the treatment of immune checkpoint inhibitor (ICI)-resistant glioblastoma. The grant will fund two phases of the project: 1) Optimizing a closed, scalable, and commercially viable HSC expansion manufacturing platform; and...
- The National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded Absco Therapeutics, Inc. (Abscotx) a $406,500 project grant on September 17, 2025. The grant funding supports Abscotx's development of a novel intratumoral delivery system utilizing the Oncolymer platform to enhance solid tumor immunotherapy. The core innovation is a thermoresponsive hydrogel that transforms from a liquid to a solidified depot upon injection, enabling targeted,...
- This $129,289 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports the development and evaluation of lysosome-targeting chimeras (LYTACs) to degrade immune checkpoint proteins and enhance immunoradiotherapy for head and neck cancer (HNC). The key products and services to be delivered under this grant include: Development of LYTACs targeting immunosuppressive proteins...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...